Epizyme, Inc. , a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that the U.S. Food and Drug Administration has accepted the company’s Investigational New Drug application for tazemetostat for the treatment of adults with mesothelioma characterized by BAP1 loss-of-function. In the third quarter of this year, the company plans to initiate a phase 2 study in patients with mesothelioma.
